The rarity of soft tissue sarcomas has historically made the definition of genomic drivers of their initiation and progression difficult. Through copy number, whole exome and transcriptome analyses, however, common events associated with these lesions have recently been defined. The focus of our laboratory is to understand how these events, in the context of a mesenchymal cell background, promote sarcomagenesis. Using in vitro and in vivo techniques, we hope to use this information to identify novel predictive markers and therapeutic targets with potential to inform patient care.
Chmielecki J*, Crago AM*, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M (*equal contribution). Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nature Genetics Feb 2013; 45:131-132. PMCID: PMC3984043.
Crago, AM, Chmielecki, J., Rosenberg, M., O’Connor, R., Byrne, C., Wilder, FG, Agius, P, Socci, ND, Qin, LX, Meyerson, M, Hameed, M, and Singer S. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes, Chromosomes and Cancer, Oct 2015; 54:606-15. PMCID:PMC26171757.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Aimee Crago discloses the following relationships and financial interests:
Springworks Therapeutics Provision of Services
WebMD Provision of Services
Wolters Kluwer Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at email@example.com.